TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05417568

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
Study: NCT05746039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Once weekly subcutaneous injection
Study: NCT05842057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioDFence G3 Placental Tissue Membrane
Description: The BioDFence G3 Placental Tissue Membrane is a three-layer tissue allograft consisting of amnion-chorion-amnion. Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP. The membrane will be cut into two longitudinal pieces and placed over each neurovascular bundle separately.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robot-Assisted Radical Prostatectomy
Description: Robot-assisted surgical removal of the prostate, administered standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Prostatectomy
Description: Robot-assisted surgical removal of the prostate, administered standard of care.
Study: NCT05959707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: PGDM1400LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: PGDM1400LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: PGDM1400LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
Study: NCT05008510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabizabulin
Description: Sabizabulin (Veru-111)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab Govitecan-hziy
Description: Sacituzumab govitecan-hziy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabizabulin/Sacituzumab govitecan-hziy Combo
Description: Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
Study: NCT05959707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
Study: NCT04480645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CivaDerm
Description: radioactive bandage
Study: NCT05516199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal breastmilk expression
Description: Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding consultation
Description: 60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding consultation
Description: 60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
Study: NCT05202522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual GERAS DANCE
Description: Dance is a form of aerobic exercise that involves multicomponent training with physical, cognitive, and social dimensions and may have synergetic benefits when delivered in combination. GERAS DANcing for Cognition and Exercise (DANCE), a community-based rehabilitation program for older adults with cognitive decline and/or mobility impairments, has been adapted for virtual delivery through videoconferencing systems. Participants will receive twice-weekly (one hour per session) virtual dance sessions for a total of 6 weeks.
Study: NCT05490667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib combined with chemotherapy for desmoid tumors
Study: NCT06152120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-facilitated advance care planning intervention
Description: The intervention consists of two components:~Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations.~Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences.
Study: NCT05233826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: Intranasal, live attenuated vaccine against SARS-CoV-2
Study: NCT06390735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mommy ReachOut Intervention
Description: The momy reachOut intervention is a web-based psycho-education with 4 sessions, released over a two week period.
Study: NCT05914610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envolimab
Description: Envolizumab 300mg, D1, ih, Q3W 4-6cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur
Description: Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles
Study: NCT06535074

Intervention type: OTHER
Intervention: Detecting changes in lung volume with hypoxemia episodes
Description: Electrical impedance tomography (EIT) will be used to assess changes in lung aeration prior and during hypoxemia episodes to classify them into four different subtypes.~FE subtype: Defined as HEs preceded by reduction in EELI below the baseline.~Apnea subtype: Defined as HEs not meeting the criteria for FE subtype and preceded by cessation of breathing.~Mixed subtype: Defined as HEs meeting the criteria for both FE and apnea subtypes.~Unclassified: Defined as HEs not categorized into any of the above parameters.
Study: NCT06535412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-002 + SOC
Description: intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: intravenous injection of Placebo
Study: NCT06551454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Textile Solution Biofeedback Method
Description: The Smart Textile Solution Biofeedback Method for injury prevention in youth league football players integrates sensors within socks to monitor key biomechanical indicators such as center of pressure and plantar pressure of the foot in real-time. By providing immediate feedback and alerts on potential injury risks, the system helps players adjust their techniques during training sessions and prevent injuries during training and games.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Textile Solution Biofeedback Method
Description: The Smart Textile Solution Biofeedback Method for injury prevention in youth league football players integrates sensors within socks to monitor key biomechanical indicators such as center of pressure and plantar pressure of the foot in real-time. By providing immediate feedback and alerts on potential injury risks, the system helps players adjust their techniques during training sessions and prevent injuries during training and games.
Study: NCT05224206

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta burst stimulation
Description: Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation
Description: Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
Study: NCT05496595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCBY02
Description: A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCBY02
Description: A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
Study: NCT05298085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study treatment will be administered intranasally daily for 12 weeks.
Study: NCT05418257

Intervention type: OTHER
Intervention: (exposure) telemedicine
Description: medical counseling or treatment only using phone
Study: NCT05658289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coracoid Transfer
Description: For patients randomized to the active comparator group, the coracoid process and conjoined tendon will be cut and transferred to the anterior rim of the glenoid through an incision in the subscapularis muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Tibia Allograft with Bankart repair
Description: For the experimental group, a distal tibia allograft will be prepped, cut (20mm x 10mm x 15mm), and inserted into the anterior aspect of the shoulder through a far medial portal. The distal tibia allograft will be attached to the anterior glenoid using cannulated screws. A soft tissue repair, Bankart repair, is performed above the graft.
Study: NCT06290258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation has been applied to patients with autism spectrum disorder in recent years. Fecal microbiota of healthy donors can be transplanted to patients through colonoscopy. Before donation, donors were comprehensively screened to rule out gastrointestinal symptoms and infections. Patients will receive colon preparation before transplantation. After the intervention, patients will have to stay in bed and be monitored for 24 hours to assure safety.
Study: NCT06569108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN057
Description: KN057 will be administered subcutaneously once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN057
Description: KN057 will be administered subcutaneously once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN057
Description: KN057 will be administered subcutaneously once a week.
Study: NCT06568861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)
Study: NCT05291156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week.
Study: NCT05879744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-978
Description: CD19xCD3 T cell engager

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-978
Description: CD19xCD3 T cell engager
Study: NCT05291156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered as a 1-hour IV infusion at flat dose of 800 mg every 2-week treatment cycle.
Study: NCT05152407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)
Description: Serums will be topically applied twice a day (mornings and evenings).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)
Description: Serums will be topically applied twice a day (mornings and evenings).
Study: NCT05166473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group (n=21)
Description: This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (n=21)
Description: After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises.
Study: NCT06542861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency simulation-based team training
Description: The intervention is a standardized high-frequency training program as described in intervention arm. It is supported by four preliminary initiatives:~1. 15 extra pediatric simulation facilitators were educated, bringing the total number up to 40.~2. A two-day pre-intervention workshop for all pediatric simulation facilitators.~3. A scenario bank containing standardized scenarios on common pediatric and neonatal emergencies was created and made accessible for simulation facilitators to support consistency in the intervention.~4. Purchase of equipment. Eight Leardal manikins. Four SimPads. Four monitors. During the intervention year, these will rotate between the pediatric departments.
Study: NCT05212831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inogen One® G4
Description: Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
Study: NCT04778007

Intervention type: OTHER
Intervention: Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire
Description: The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.

Intervention type: OTHER
Intervention: Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire
Description: The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
Study: NCT06336226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachio basilic arterio venous fistula one stage versus two stage
Description: Comparative study between one stage brachio basilic arterio venous fistula versus two stage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachio basilic arterio venous fistula one stage versus two stage
Description: Comparative study between one stage brachio basilic arterio venous fistula versus two stage
Study: NCT05610982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Program
Description: The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
Study: NCT05983029

Intervention type: DIAGNOSTIC_TEST
Intervention: Intergluteal Cleft
Description: Marking of intersection between inferior aspect of the intergluteal cleft and the horizontal intercristal line

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuraxial Midline
Description: Marking of intersection between the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line

Intervention type: DIAGNOSTIC_TEST
Intervention: Horizontal Distance between Vertical Markings
Description: The horizontal distance between these two vertical marks will be measured at the level of the intercristal line
Study: NCT05920018

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated linoleic acid (CLA/Tonalin® FFA 80)
Description: Daily application of two capsules p.o., i.e. 2g/day for 48 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltose placebo
Description: Daily application of four sachets for 48 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil placebo
Description: Daily application of two capsules p.o for 48 weeks
Study: NCT05050357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal intrauterine device
Description: insertion of hormonal IUD during menstrual period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestins Norethindrone
Description: oral ethisteron twice daily for three months
Study: NCT05410574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based Behavioral Weight Loss Treatment
Description: The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based Behavioral Weight Loss Treatment
Description: The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts